glp-1 and kidney disease receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal GLP-1s lower BMI, preserve kidney

GLP-1s, Ozempic, Wegovy, and Mounjaro, are changing how many people eat

For a clinic built on trust and safety, that silence speaks loudly

Clients often see improvements in: Daytime energy and focus Sleep quality and recovery Mood and mental clarity Workout stamina and metabolic support We also offer combination injections like our Super Shot, which includes B12, ALA, and Vitamin D designed to enhance your weight loss or hormone therapy program

Current evidence suggests GLP-1 receptor agonists have a neutral effect on fracture risk, though bone mineral density changes may occur indirectly through substantial weight loss